MORE►
Pfizer
Left to right: Dr. Shehnaaz Suliman, CEO and board member of ReCode; and David Lockhart, president and chief science officer. [Photos: Jennifer Leahy]
Dallas-Founded Biopharma Firm Raises $120M to Expand its Pipeline
by Kevin Cummings | Jun 29, 2022
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases.
With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
by Dallas Innovates | Staff Report |
Feb 25, 2022
In this week's roundup of hires, promotions, and accolades in North Texas, you'll also find news from the Richardson Chamber, PICKUP, BPS Technology, the Frontiers of Flight Museum, UNT Health Science Center at Fort Worth, and Giving DNA.
Plus, Governor Abbott appoints three North Texans to the Governor's Commission for Women.
MORE►
by David Seeley |
Jan 27, 2022
Some insights: TikTok is the world's fastest-growing brand; tech is the most valuable industry at $1.3 trillion; retail continues to thrive with Walmart jumping up a spot; the pharma sector showed faster growth over the last two years than any other; and the U.S. and China continue to dominate.
We spoke with the managing director of the company's Dallas Americas HQ about his firm's Texas business and plans for U.S. growth.
MORE►
